Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis
- PMID: 20472091
- DOI: 10.1016/j.micinf.2010.04.010
Lactic acid bacteria colonization and clinical outcome after probiotic supplementation in conventionally treated bacterial vaginosis and vulvovaginal candidiasis
Abstract
This randomized double-blind placebo controlled study assessed the vaginal colonization of lactic acid bacteria and clinical outcome. Vaginal capsules containing L gasseri LN40, Lactobacillus fermentum LN99, L. casei subsp. rhamnosus LN113 and P. acidilactici LN23, or placebos were administered for five days to 95 women after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis. Vulvovaginal examinations and vaginal samplings were performed before and after administration, after the first and second menstruation, and after six months. Presence of LN strains was assessed using RAPD analysis. LN strains were present 2-3 days after administration in 89% of the women receiving LN strains (placebo: 0%, p < 0.0001). After one menstruation 53% were colonized by at least one LN strain. Nine percent were still colonized six months after administration. Ninety-three percent of the women receiving LN strains were cured 2-3 days after administration (placebo: 83%), and 78% after one menstruation (placebo: 71%) (ns). The intervention group experienced less malodorous discharge 2-3 days after administration (p = 0.03) and after the second menstruation (p = 0.04), compared with placebo. In summary, five days of vaginal administration of LN strains after conventional treatment of bacterial vaginosis and/or vulvovaginal candidiasis lead to vaginal colonization, somewhat fewer recurrences and less malodorous discharge.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection.BMC Infect Dis. 2015 Jul 3;15:255. doi: 10.1186/s12879-015-0971-3. BMC Infect Dis. 2015. PMID: 26137971 Free PMC article. Clinical Trial.
-
[Lactofem--using of vital lactic acid bacteria in the cases of vaginal microflora imbalance].Akush Ginekol (Sofiia). 2006;45(6):55-8. Akush Ginekol (Sofiia). 2006. PMID: 17168486 Bulgarian.
-
An exploratory pilot study evaluating the supplementation of standard antibiotic therapy with probiotic lactobacilli in south African women with bacterial vaginosis.BMC Infect Dis. 2019 Sep 18;19(1):824. doi: 10.1186/s12879-019-4425-1. BMC Infect Dis. 2019. PMID: 31533663 Free PMC article. Clinical Trial.
-
The role of lactobacillus probiotics in the treatment or prevention of urogenital infections--a systematic review.J Chemother. 2009 Jun;21(3):243-52. doi: 10.1179/joc.2009.21.3.243. J Chemother. 2009. PMID: 19567343 Review.
-
Persistence of Lactobacilli in Postmenopausal Women - A Double-Blind, Randomized, Pilot Study.Gynecol Obstet Invest. 2017;82(2):144-150. doi: 10.1159/000446946. Epub 2016 Jul 5. Gynecol Obstet Invest. 2017. PMID: 27376550 Review.
Cited by
-
Probiotics in the Management of Vulvovaginal Candidosis.J Clin Med. 2024 Aug 30;13(17):5163. doi: 10.3390/jcm13175163. J Clin Med. 2024. PMID: 39274376 Free PMC article. Review.
-
The Role of Probiotics in the Treatment of Vulvovaginal Candidiasis: A Systematic Review and Meta-Analysis.Ethiop J Health Sci. 2023 Sep;33(5):881-890. doi: 10.4314/ejhs.v33i5.18. Ethiop J Health Sci. 2023. PMID: 38784519 Free PMC article. Review.
-
Vaginal and Rectal microbiome changes following administration of a multi-species antenatal probiotic: A randomized control trial.Gut Microbes Rep. 2024;1(1):1-10. doi: 10.1080/29933935.2024.2334311. Epub 2024 Apr 19. Gut Microbes Rep. 2024. PMID: 38708373
-
Vaginal microbiota: Potential targets for vulvovaginal candidiasis infection.Heliyon. 2024 Mar 2;10(5):e27239. doi: 10.1016/j.heliyon.2024.e27239. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38463778 Free PMC article. Review.
-
Lactobacillus crispatus CCFM1339 Inhibits Vaginal Epithelial Barrier Injury Induced by Gardnerella vaginalis in Mice.Biomolecules. 2024 Feb 18;14(2):240. doi: 10.3390/biom14020240. Biomolecules. 2024. PMID: 38397477 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous